A method for producing tricyclo[5.2.1.0.sup.2,6]decane-2-carboxylate according to the present invention is a method for producing tricyclo[5.2.1.0.sup.2,6]decane-2-carboxylate, containing reacting tricyclo[5.2.1.0.sup.2,6]deca-3-ene in a dilute solution containing the tricyclo[5.2.1.0.sup.2,6]deca-3-ene with carbon monoxide in the presence of an acid catalyst, followed by reaction with an alcohol, wherein the dilute solution contains 100 parts by mass or more of a tricyclo[5.2.1.0.sup.2,6]decane isomer mixture based on 100 parts by mass of the tricyclo[5.2.1.0.sup.2,6]deca-3-ene, the tricyclo[5.2.1.0.sup.2,6]decane isomer mixture contains endo-tricyclo[5.2.1.0.sup.2,6]decane (Endo form of TCD) and exo-tricyclo[5.2.1.0.sup.2,6]decane (Exo form of TCD), and a constituent ratio thereof (Endo form of TCD/Exo form of TCD) is greater than 1.0.

To provide a fluorinated ether compound, a fluorinated ether composition and a coating liquid excellent in chemical resistance, an article having a surface layer excellent in chemical resistance and a method for producing it, and a method for producing a fluorinated ether compound excellent in chemical resistance.

A fluorinated ether compound which has a first partial structure represented by the following formula (1) and a second partial structure represented by the following formula (2), and which has at least five first partial structures, or has at least two second partial structures:

—OR.sup.f12—  (1)

—OR.sup.f13—  (2)

wherein R.sup.f12 is a C.sub.1-6 fluoroalkylene group, and R.sup.f13 is a group having a fluorinated cyclic structure which may have a hetero atom.

To provide a fluorinated ether compound, a fluorinated ether composition and a coating liquid excellent in chemical resistance, an article having a surface layer excellent in chemical resistance and a method for producing it, and a method for producing a fluorinated ether compound excellent in chemical resistance.

A fluorinated ether compound which has a first partial structure represented by the following formula (1) and a second partial structure represented by the following formula (2), and which has at least five first partial structures, or has at least two second partial structures:

—OR.sup.f12—  (1)

—OR.sup.f13—  (2)

wherein R.sup.f12 is a C.sub.1-6 fluoroalkylene group, and R.sup.f13 is a group having a fluorinated cyclic structure which may have a hetero atom.

The present disclosure relates to a process for the preparation of 4,5-dihydroxy-2-(4-methylbenzyl)isophthalonitrile, to use of a compound which is 2-methoxy-5-(4-methylbenzyl)phenol, (3-hydroxy-4-methoxyphenyl)(p-tolyl)methanone, 2-methoxy-5-(4-methylbenzoyl)phenyl 2-chloroacetate, 4-methylbenzoyl chloride, 2-methoxyphenyl 2-chloroacetate or 2-methoxyphenol in the preparation of 4,5-dihydroxy-2-(4-methylbenzyl)isophthalonitrile and to a compound which is 4-hydroxy-5-methoxy-2-(4-methylbenzyl)isophthalaldehyde dioxime or 4-hydroxy-5-methoxy-2-(4-methylbenzyl)isophthalaldehyde and use thereof in the preparation of 4,5-dihydroxy-2-(4-methylbenzyl)isophthalonitrile. 4,5-Dihydroxy-2-(4-methylbenzyl)isophthalonitrile is a COMT inhibitor.

The present disclosure relates to a process for the preparation of 4,5-dihydroxy-2-(4-methylbenzyl)isophthalonitrile, to use of a compound which is 2-methoxy-5-(4-methylbenzyl)phenol, (3-hydroxy-4-methoxyphenyl)(p-tolyl)methanone, 2-methoxy-5-(4-methylbenzoyl)phenyl 2-chloroacetate, 4-methylbenzoyl chloride, 2-methoxyphenyl 2-chloroacetate or 2-methoxyphenol in the preparation of 4,5-dihydroxy-2-(4-methylbenzyl)isophthalonitrile and to a compound which is 4-hydroxy-5-methoxy-2-(4-methylbenzyl)isophthalaldehyde dioxime or 4-hydroxy-5-methoxy-2-(4-methylbenzyl)isophthalaldehyde and use thereof in the preparation of 4,5-dihydroxy-2-(4-methylbenzyl)isophthalonitrile. 4,5-Dihydroxy-2-(4-methylbenzyl)isophthalonitrile is a COMT inhibitor.

Treprostinil is a synthetic prostacyclin derivative with thrombocyte aggregation inhibitory and vasodilatory activity. Treprostinil can be administered in subcutaneous, intravenous, inhalable, or oral forms. Disclosed is a method for the preparation of treprostinil of formula I and its amorphous form, anhydrate form, monohydrate form, and polyhydrate form salts with bases. In the disclosed method, the chiral center in the 3-hydroxyoctyl substituent is formed at the end of the synthesis, so that the method is robust and well scalable. Also disclosed are treprostinil intermediates and the preparation of the intermediates.

##STR00001##

Treprostinil is a synthetic prostacyclin derivative with thrombocyte aggregation inhibitory and vasodilatory activity. Treprostinil can be administered in subcutaneous, intravenous, inhalable, or oral forms. Disclosed is a method for the preparation of treprostinil of formula I and its amorphous form, anhydrate form, monohydrate form, and polyhydrate form salts with bases. In the disclosed method, the chiral center in the 3-hydroxyoctyl substituent is formed at the end of the synthesis, so that the method is robust and well scalable. Also disclosed are treprostinil intermediates and the preparation of the intermediates.

##STR00001##

Treprostinil is a synthetic prostacyclin derivative with thrombocyte aggregation inhibitory and vasodilatory activity. Treprostinil can be administered in subcutaneous, intravenous, inhalable, or oral forms. Disclosed is a method for the preparation of treprostinil of formula I and its amorphous form, anhydrate form, monohydrate form, and polyhydrate form salts with bases. In the disclosed method, the chiral center in the 3-hydroxyoctyl substituent is formed at the end of the synthesis, so that the method is robust and well scalable. Also disclosed are treprostinil intermediates and the preparation of the intermediates.

##STR00001##

The present invention relates to a process for preparing a (1S,2R)-(2-hydroxy-3,5,5-trimethyl-3-cyclopentenyl)methyl carboxylate compound of the following general formula (S,R)-(2), wherein R.sup.1 represents a monovalent hydrocarbon group having 1 to 6 carbon atoms, and a bold wedged bond represents the absolute configuration, and a (1R,2S)-(2-acetoxy-3,5,5-trimethyl-3-cyclopentenyl)methyl carboxylate compound of the following general formula (R,S)-(3), wherein R.sup.1 is as defined above, a hashed wedged bond represents the absolute configuration, and Ac represents an acetyl group, the process comprising: subjecting a (1RS,2SR)-(2-hydroxy-3,5,5-trimethyl-3-cyclopentenyl)methyl carboxylate compound of the following general formula (RS,SR)-(2), wherein R.sup.1 is as defined above, and a hashed unwedged bond represents a relative configuration, to a kinetic resolution reaction with a lipase in the presence of vinyl acetate to obtain the (1S,2R)-(2-hydroxy-3,5,5-trimethyl-3-cyclopentenyl)methyl carboxylate compound ((S,R)-(2)) and the (1R,2S)-(2-acetoxy-3,5,5-trimethyl-3-cyclopentenyl)methyl carboxylate compound ((R,S)-(3)). ##STR00001##

The present invention relates to a process for preparing a (1S,2R)-(2-hydroxy-3,5,5-trimethyl-3-cyclopentenyl)methyl carboxylate compound of the following general formula (S,R)-(2), wherein R.sup.1 represents a monovalent hydrocarbon group having 1 to 6 carbon atoms, and a bold wedged bond represents the absolute configuration, and a (1R,2S)-(2-acetoxy-3,5,5-trimethyl-3-cyclopentenyl)methyl carboxylate compound of the following general formula (R,S)-(3), wherein R.sup.1 is as defined above, a hashed wedged bond represents the absolute configuration, and Ac represents an acetyl group, the process comprising: subjecting a (1RS,2SR)-(2-hydroxy-3,5,5-trimethyl-3-cyclopentenyl)methyl carboxylate compound of the following general formula (RS,SR)-(2), wherein R.sup.1 is as defined above, and a hashed unwedged bond represents a relative configuration, to a kinetic resolution reaction with a lipase in the presence of vinyl acetate to obtain the (1S,2R)-(2-hydroxy-3,5,5-trimethyl-3-cyclopentenyl)methyl carboxylate compound ((S,R)-(2)) and the (1R,2S)-(2-acetoxy-3,5,5-trimethyl-3-cyclopentenyl)methyl carboxylate compound ((R,S)-(3)). ##STR00001##